Universidad de Salamanca-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2013

  1. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines

    Cancer Letters, Vol. 334, Núm. 2, pp. 302-310

2012

  1. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles

    Nanomedicine, Vol. 7, Núm. 5, pp. 679-690

2011

  1. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma

    Journal of Controlled Release, Vol. 156, Núm. 3, pp. 421-426

2010

  1. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts

    Clinical Cancer Research, Vol. 16, Núm. 7, pp. 2046-2054

  2. Lipid raft-targeted therapy in multiple myeloma

    Oncogene, Vol. 29, Núm. 26, pp. 3748-3757

2009

  1. Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 877, Núm. 31, pp. 4035-4041

2008

  1. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 68, Núm. 2, pp. 207-213

2004

  1. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: Application to cell uptake studies and characterization of drug delivery systems

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 810, Núm. 1, pp. 85-92